It’s been a very busy, big and ambitious year for Bioasis Technologies Inc. (TSX-V.BTI, OTC:BIOAF, Forum) – a biopharmaceutical company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. And while much has been accomplished by this cutting-edge biotech in 2020, much more exciting news is expected in the pipeline for 2021.
In a relatively short period of time, the Company has generated real shareholder value by developing and commercializing its proprietary brain delivery technology – XB3 – to make life-saving drugs brain-penetrant and deliver those drugs at a therapeutically relevant dose.
In this must-hear end-of-year vodcast, Stockhouse Media’s Dave Jackson was joined by CEO Dr. Deborah Rathjen to talk more about the genesis of the amazing xB3 platform, its long-term investment potential, and all things Bioasis moving forward into 2021.
Stockpod #13: Transeastern Power Trust
Stockpod #12: TransGaming
Stockpod #11: Tweed/Bedrocan
Stockpod #10: MGX Minerals
Stockpod #9: Nutritional High
Stockpod #8: Invictus MD Strategies
Stockpod #7: Manitok Energy
Stockpod #6: ExGen Resources
Stockpod #5: The East Africa Metals saga
Stockpod #4: Tickertrax columnist Danny Deadlock
Stockpod #3: Naturally Splendid
Stockpod #2: First Growth Holdings
Stockpod #1: Supreme Pharmaceuticals
Stockhouse Drunken Roundtable podcast, 29/06/15
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
U.S Property Podcast
Aligned Money Show
Dubai Property Podcast
The Ramsey Show
The Clark Howard Podcast